Pierre Fabre Targets 600 Million Euros in Asia with Annual Regional Outlay
In this article (9)
Laboratoires Pierre Fabre plans to invest 60 million euros annually across Asia-Pacific to double regional revenue by 2032, prioritizing Asian markets over the United States.
The French maker of Eau Thermale Avene and Klorane closed 2025 with 3.2 billion euros in worldwide sales, with the regional expansion designed to lift global revenue past 5 billion euros by 2032.
Asia-Pacific excluding China brought in 170 million euros in 2025, while the Chinese dermo-cosmetics business delivered about 180 million euros. Chief executive Eric Ducournau plans to raise ex-China regional revenue past 300 million euros by 2032 and roughly double sales inside China, deploying an annual investment run-rate equal to 20 per cent of regional revenue.
Splitting Dermocosmetics and Drug Lines
Group revenue currently splits 55 per cent to dermo-cosmetics and 45 per cent to pharmaceuticals. Brands such as Eau Thermale Avene, Ducray and A-Derma anchor the consumer skincare portfolio, while oncology, rare diseases and medical dermatology make up the prescription pipeline.
Ducournau intends to equalize both divisions at a 50-50 share globally by 2032. That balancing hinges on Asian distribution, where pharmaceuticals currently represent 35 per cent of regional net sales.
External licensing and biotechnology partnerships feed the drug pipeline. Oncology has already expanded from 19 per cent of pharmaceutical revenue in 2018 to 41 per cent in 2025, targeting colorectal, lung and melanoma cancers.
Building Production Closer to Asian Shelves
Supply snarls during the pandemic prompted the group to re-evaluate factory footprints. Pierre Fabre will now place dedicated manufacturing capacity inside the region for both consumer formulas and pharmaceuticals rather than shipping finished units entirely out of Europe.
“Oncology has already expanded from 19 per cent of pharmaceutical revenue in 2018 to 41 per cent in 2025, targeting colorectal, lung and melanoma cancers.”
Clinical trials will also shift eastward to account for local patient populations. Rather than rolling out European trial data unchanged, the company is tying clinical research directly to hospital networks and doctors across East and Southeast Asia.
Eight regional markets currently form the footprint: mainland China, Japan, South Korea, Australia, Taiwan, Hong Kong, Vietnam and Singapore.
Rival Strategy and Malaysia Expansion
Most European beauty and drug conglomerates lean on North American channels to fund top-line growth. Pierre Fabre is taking the opposite route, directing commercial budgets into Asia where consumer dermo-cosmetics demand outpaces Western retail pharmacy counters.
For regional pharmacy chains, department stores and e-commerce platforms, this pivot channels larger trade marketing budgets and faster inventory replenishment into Southeast Asian channels. The risk lies in execution: competing against established Japanese beauty giants and entrenched European conglomerates demands heavy shelf-space spending in retail environments that operate on tight vendor margins.
Malaysia sits next on the retail roadmap. Ducournau pointed to Malaysia alongside Vietnam as priority markets for footprint expansion, citing fast consumer spending growth across urban centres.
Regional Hub Operations
Singapore has anchored the company’s regional headquarters since 2014, operating as the initial launch pad for new formulas across Southeast Asia. The city-state accommodates roughly 60 staff out of the group’s 350 regional employees, according to Jairo Pardey, general manager for Singapore.
Maintaining Singapore as the commercial base ensures direct oversight as Pierre Fabre establishes marketing, regulatory and clinical trial teams on the ground in target territories.
The company is now tracking toward an 8 per cent group-wide annual growth rate, alongside double-digit annual gains across Asia-Pacific toward the 2032 deadline.
Questions & Answers
Q.How does Pierre Fabre plan to overhaul its regional manufacturing and clinical trial operations?
How does Pierre Fabre plan to overhaul its regional manufacturing and clinical trial operations?
The company will establish dedicated regional manufacturing capacity for both consumer formulas and pharmaceuticals rather than shipping finished goods from Europe. In addition, clinical trials will shift eastward, connecting research directly with hospital networks and doctors across East and Southeast Asia.
Q.What specific revenue milestones must the company reach in Asia-Pacific by 2032?
What specific revenue milestones must the company reach in Asia-Pacific by 2032?
Chief executive Eric Ducournau plans to raise ex-China regional revenue past 300 million euros and roughly double sales inside China by 2032. Supported by an annual 60 million euro outlay, the regional push is designed to help lift global sales past 5 billion euros.
Q.Why is the group prioritising Asian expansion over the North American market?
Why is the group prioritising Asian expansion over the North American market?
Consumer demand for dermo-cosmetics in Asia is outpacing Western retail pharmacy counters, prompting the group to divert commercial budgets away from North America. However, the strategy carries execution risks, requiring heavy shelf-space spending against established Japanese beauty brands and European conglomerates on tight vendor margins.
Q.Which Southeast Asian countries are targeted next for retail expansion?
Which Southeast Asian countries are targeted next for retail expansion?
Malaysia is next on the retail roadmap, with chief executive Eric Ducournau highlighting it alongside Vietnam as a priority market for footprint expansion. The company is targeting both countries due to accelerating consumer spending across urban centres, overseen from its regional commercial hub in Singapore.
Reader pulse
Can Pierre Fabre double Asian revenue by 2032?
20,969 votes so far